Page 1,283«..1020..1,2821,2831,2841,285..1,2901,300..»

The 5 best acupuncture spots in Anaheim – Yahoo News

Posted: November 8, 2019 at 1:46 pm

Photo: Golden Roots Acupuncture & Herbal Medicine/Yelp

Looking for the best acupuncture options near you?

Hoodline crunched the numbers to find the top acupuncture spots around Anaheim, using both Yelp data and our own secret sauce to produce a ranked list of the best spots to venture next time you're in the market for acupuncture.

Anaheim-area consumers historically spend more in November at health and beauty businesses than other months of the year, according to data on local business transactions from Womply, a provider of online reputation management and direct response marketing for small businesses. The average amount spent per customer transaction at Anaheim-area health and beauty businesses grew to $53 for the metro area in November of last year, second only to December with an average of $54, and 3% higher than the average for the rest of the year.

Hoodline offers data-driven analysis of local happenings and trends across cities. Links included in this article may earn Hoodline a commission on clicks and transactions.

First on the list is Evolve Integrative Health. Located at 6200 E. Canyon Rim Road, Suite 109D in Anaheim Hills, the chiropractor and acupuncture spot is the highest-rated acupuncture spot in Anaheim, boasting five stars out of 49 reviews on Yelp.

Next up is West Anaheim's Peebro Skin & Total Health Care, situated at 408 S. Beach Blvd., Suite 108. With 4.5 stars out of 102 reviews on Yelp, the medical spa, acupuncture and skin care spot has proven to be a local favorite.

West Anaheim's Jaein Acupuncture & Herbal Medicine, located at 3441 W. Ball Road, Suite E, is another top choice, with Yelpers giving the acupuncture, tui na and pain management specialist spot five stars out of 37 reviews.

Golden Roots Acupuncture & Herbal Medicine, a Chinese medicine specialist and acupuncture and massage therapist spot in Northwest Anaheim, is another much-loved go-to, with five stars out of 19 Yelp reviews. Head over to 1781 W. Romneya Drive, Suite D to see for yourself.

Story continues

Last but not least, over in Anaheim Hills, check out Hands on Wellness Center, which has earned 4.5 stars out of 40 reviews on Yelp. You can find the chiropractor, acupuncture and massage therapist spot at 5100 E. La Palma Ave., Suite 104.

This story was created automatically using local business data, then reviewed and augmented by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.

Excerpt from:
The 5 best acupuncture spots in Anaheim - Yahoo News

Posted in Integrative Medicine | Comments Off on The 5 best acupuncture spots in Anaheim – Yahoo News

Expanding the horizons of environmental research – University of Miami

Posted: November 8, 2019 at 1:46 pm

Supported by the Office of the Provost, the first Abess Scholars have wide latitude to bridge the gap between science and environmental policy.

One plans to invite studentsto accompany her, virtually, onall-female expeditionstothe Arctic andAntarctica.Another intends to explore the realities and mythos of barrier islands through the ever-shifting sands of Captiva Island and the musings of its most famous resident. A third is organizing a workshop on the connections between climate change, water insecurity, and migration.

They are all members of the inaugural class of Abess Scholars, eight researchers who through their innovative work have advanced the Leonard and Jayne Abess Center for Ecosystem Science and Policys mission at the University of Miami to create interdisciplinary initiatives that bridge the gap between science and environmental policy.

With special support from the Office of the Provost, the first Abess Scholars, who include seven faculty members from five schools or colleges and one award-winning author, have wide latitude to pursue activities that will increase interdisciplinary environmental education, research, and outreach across the University and the broader community.

Their energy and innovative approaches are inspirational to me and to Gina Maranto, my colleague at the Abess Center who has been instrumental in developing the program,said Abess Center Director Kenny Broad, professor in the Rosenstiel School of Marine and Atmospheric Sciences Department of Marine Ecosystems and Society and the 2011 National Geographic Explorer of the Year. The core goal of the Abess Center is to connect different players across the University who can address real-world environmental problems and each Abess Scholar now has the opportunity to amplify the Abess Centers mission in their own creative and exciting way.

Provost Jeffrey Duerk, who over his career has collaborated with multiple teams from multiple disciplines to develop biomedical imaging technology, is leading the effort to integrate the team science approach into the Universitys burgeoning culture of interdisciplinary inquiry. He said the Abess Centers 30-odd affiliate faculty are uniquely positioned to enhance interdisciplinary teaching and scholarship across the University, a key goal of the Roadmap to Our New Century.

Our mission as a University is to be a hub for the kind of collaborative research that can address such complex problems as climate change or chronic disease, but that cant happen without a cadre of experienced interdisciplinary practitioners, Duerk said. The Abess Scholars program will strengthen the Abess Center and the University by identifying and cultivating affiliated faculty who can espouse the values of creative interdisciplinary collaboration and mission-driven research pertaining to one of the worlds most complex and over-arching challenges, the environment.

In addition to the Abess Scholars, the Office of the Provost supports a number of initiatives designed to advance interdisciplinary inquiry across the University. They include the University of Miami Laboratory for Integrative Knowledge, or U-LINK, and the Louis Glaser Fellowship in Integrated Teaching and Learning, which is accepting proposals through Dec. 1.

Launched in 2016, U-LINK awards up to three years of funding to multidisciplinary teams who are tackling complex problems. The Glaser fellowship is designed to give faculty the time and resources to expand their knowledge beyond their primary discipline and design new, experimental, cross-disciplinary undergraduates courses.

Three of the inaugural Abess Scholars, who will receive funds and support for one year with the possibility of a two-year extension, are also members of different U-LINK teams, and all but one were chosen from the ranks of the Abess Centers affiliated faculty. The honorees are:

Natalie Barefoot, School of Law

The practitioner in residence and lecturer in law for the School of Laws Environmental Justice Clinic, Barefoot supervises two class-action toxic torts cases and projects related to policies and practices that affect low-income and minority communities in Florida. Before joining UM, she was the executive director of Cet Law, a nonprofit that advances laws and policies to protect cetaceanswhales, dolphins, and porpoisesand their habitats. For her Abess Center project, she plans to engage studentsin climate change and biodiversity issues and inspire young women to explore STEM fieldsby bringing them, through remote classrooms and video, on two all-female expeditions, one to theArctic Circle this November, and the other to Antarctica in November 2020.

Alberto Cairo, School of Communication

The Knight Chair in Visual Journalism, an associate professor in the Department of Journalism and Media Management, and a member of the HURAKAN U-LINK team that aims to improve hurricane forecast products, Cairo teaches courses and has written text books about infographics, data visualization, and data journalism. He just published his first book for the general public, How Charts Lie, which explains how graphs, charts, and maps can mislead readers. For his project, Cairo plans a workshop for the UM community to demystify the graphical literacy that is now so essential to navigating our data-driven world.

Kenneth Feeley, College of Arts and Sciences

The Smathers Chair of Tropical Tree Biology and associate professor in the Department of Biology, Feeley draws on both natural history and advanced empirical modeling to study the ecology and biogeography of tropical forests, specifically how they are affected by large-scale anthropogenic disturbances such as climate change, deforestation, and habitat fragmentation. Through his work, he strives to understand the implications of human activities to help inform management and conservation strategies. His project is pending.

Michael Grunwald, Author

Now a senior writer for Politico magazine, Grunwald has worked at The Washington Post, The Boston Globe, and Time, and received numerous awards, including the George Polk Award, the Worth Bingham Prize, the Society of Environmental Journalists Award, and the Sierra Clubs David Brower Award for his work. The author of The Swamp: The Everglades, Florida, and the Politics of Paradise, and The New New Deal: The Hidden Story of Change in the Obama Era, he is writing a book about food production.

Joanna Lombard, School of Architecture

An architect and professor in the School of Architecture with a joint appointment in the Department of Public Health Sciences at the Miller School of Medicine, Lombard focuses on the intersection of architecture, landscape, culture, and health, especially in relation to climate change. She is a founding member of UMs Built-Environment Behavior and Health Research Group and a member of the U-LINK team exploring hyper-local adaptations to climate change. For her project, she will examine past and present perceptions of coastal resilience on Floridas barrier islands by studying the writings of artist Robert Rauschenberg at the time he adopted Captiva as his home and primary studio.

Katharine Mach, Rosenstiel School of Marine and Atmospheric Science

An associate professor in the Department of Marine Ecosystems and Society, Mach assesses climate change risks and, through innovative approaches to integrating evidence, informs the options for responding effectively and equitably to increased flooding, extreme heat, wildfire, and other hazards. A lead author for the Intergovernmental Panel on Climate Changes Sixth Assessment Report, she co-directed the scientific activities of the IPCCs Working Group II, which culminated in the Fifth Assessment Report. She is also associate deputy editor for Climatic Change and an advisory board member for the Aspen Global Change Institute and Carbon180. For her project, she plans to organize one or more science-policy workshops that examine the risks and opportunities for managing the changing climate.

Renato Molina, Rosenstiel School of Marine and Atmospheric ScienceAn engineer and economist specializing in the economics of natural resource extraction, conservation, and natural disasters, Molina is an assistant professor of environmental and resource economics, a visiting scholar at the Faculty of Natural Resources at the Pontificia Universdad Catlica de Valparaso in Chile, and a member of the U-LINK team exploring the next generation of coastal structures. He focuses on the intersection between game theory, sustainability, and institutional settings and relies on economic insight to inform responsible policymaking for environmental and natural resources management. For his project, he plans to study the effects of climate change adaptation efforts on real estate markets and the implications for vulnerable communities.

Justin Stoler, College of Arts and Sciences

An associate professor in the Department of Geography and Regional Studies, Stoler holds a secondary appointment in the Miller School of Medicines Department of Public Health Sciences and has spent a decade studying communicable diseases and water insecurity in Accra, Ghana. The co-director of the Health Geographics Lab, he employs spatial modeling techniques to explore the geographic patterns of urban health disparities and environmental influences on social and behavioral epidemiology. For his project, he is convening a workshop with population and environment scholars to explore the connections between climate change, water insecurity, and migration.

Read the original post:
Expanding the horizons of environmental research - University of Miami

Posted in Integrative Medicine | Comments Off on Expanding the horizons of environmental research – University of Miami

The Alliance for Regenerative Medicine Releases Q3 2019 Sector Report, Highlighting Industry Trends and Metrics – BioSpace

Posted: November 8, 2019 at 12:45 am

WASHINGTON, D.C., Nov. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM) today released its most recent quarterly sector report, offering an in-depth look at cell therapy, gene therapy, tissue engineering, and broader global regenerative medicine sector trends and metrics in the third quarter of 2019.

By further curating information provided by ARMs data partner Informa, the quarterly sector report details industry-specific statistics compiled from 959 cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARMs current strategic priorities.

Amanda Micklus, a senior consultant for Pharma Intelligence at Informa, provided an overview of the commercial, clinical, and regulatory environment in the third quarter of 2019. The report also features commentary from founding members of ARM in honor of the organizations 10-year anniversary. Excerpts from panels at ARMs 2019 Meeting on the Mesa included in the report highlight the continued progress and innovation in the sector.

Highlighted findings from the Q3 2019 data report include:

ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trials by phase, and significant clinical data events.

The report isavailable online here, with interactive data and downloadable graphics from the reportavailable here. For more information, please visitwww.alliancerm.orgor contact Lyndsey Scull at lscull@alliancerm.org.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 350 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visithttp://www.alliancerm.org.

Lyndsey Scull202 213 7086lscull@alliancerm.org

See more here:
The Alliance for Regenerative Medicine Releases Q3 2019 Sector Report, Highlighting Industry Trends and Metrics - BioSpace

Posted in Regenerative Medicine | Comments Off on The Alliance for Regenerative Medicine Releases Q3 2019 Sector Report, Highlighting Industry Trends and Metrics – BioSpace

AVITA Medical Added to S&P/ASX 200 Index – Business Wire

Posted: November 8, 2019 at 12:45 am

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today that the company will be added to the S&P/ASX 200 index, effective upon market open on 14 November 2019, two months after being added to the S&P/ASX 300 index.

AVITA Medicals inclusion in the S&P/ASX 200 index is a testament to the companys solid growth trajectory following our U.S. commercialization of the RECELL System combined with the strength of our de-risked pipeline of future indications beyond burns, said Dr. Mike Perry, AVITA Medicals Chief Executive Officer. We believe the market capitalization and trading liquidity of the company will continue to grow as we advance our research and development efforts to realize the full potential of our innovative regenerative medicine technology platform.

The S&P/ASX 200 Index is recognized as the institutional investable benchmark in Australia and measures the performance of the largest 200 companies based on float-adjusted market capitalization on the Australian Securities Exchange.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a REGENERATIVE EPIDERMAL SUSPENSION (RES), an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. Burn Centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

Read the rest here:
AVITA Medical Added to S&P/ASX 200 Index - Business Wire

Posted in Regenerative Medicine | Comments Off on AVITA Medical Added to S&P/ASX 200 Index – Business Wire

AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November – PRNewswire

Posted: November 8, 2019 at 12:45 am

IRVINE, Calif., Nov. 1, 2019 /PRNewswire/ --AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that it will be presenting at the following regenerative medicine and investor conferences in November:

Society for the Immunotherapy of Cancer (SITC) Annual MeetingOral PresentationPresenter: Dr. Daniela Bota, MD, PhD, University of California, Irvine; AIVITA GBM Principal InvestigatorTitle: Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastomaTime: November 6-10, 2019Location: Gaylord National Hotel & Convention Center, National Harbor, MD

The Regenerative Medicine Consortium of the Gulf Coast Consortia for Biomedical SciencesOral Presentation Presenter: Dr. Hans S. Keirstead, AIVITA Chairman and CEOTitle: Clinical and Commercial Application of Scaled Human Stem Cell DerivatesTime: November 8, 4:00 PM CTLocation: Bioscience Research Collaborative, Houston, TX

NYC Oncology Investor ConferenceOral Presentation Presenter: Dr. Hans S. Keirstead, AIVITA Chairman and CEO Title: AIVITA Corporate PresentationTime: November 12, 4:50 PM - 5:10 PMLocation: Rockefeller Center, New York, NY

Society for NeuroOncology Annual MeetingPoster PresentationTitle: Phase II trial of AV-GBM-1 (autologous dendritic cells loaded with autologous tumor associated antigens) as adjunctive therapy following primary surgery plus concurrent chemoradiation in patients with newly diagnosed glioblastoma.Time: November 20-24, 2019Location: JW Marriott Desert Ridge, Phoenix, AZ

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. All proceeds from the sale of AIVITA's skin care products support the treatment of women with ovarian cancer.

SOURCE AIVITA Biomedical, Inc.

http://aivitabiomedical.com

Read the original:
AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November - PRNewswire

Posted in Regenerative Medicine | Comments Off on AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November – PRNewswire

Regenerative Medicine May be the Answer for Your Chronic Pain – Cape May County Herald

Posted: November 8, 2019 at 12:45 am

Do you suffer from chronic knee pain, shoulder pain, hip pain, low back pain, neck pain, degenerative arthritis, bone on bone, or Neuropathy?

Have you tried over the counter medication, prescription drugs, pain medicine, physical therapy, gel shots, Cortisone injections, or surgery, all without lasting relief?

Regenerative Medicine of South Jersey offers cutting edge therapies ideal for improving joint mobility, reducing joint pain and preventing costly painful surgeries or replacements. Regenerative Medicine of South Jersey provides caring state-of-the-art treatment.

Our providers understand the daily struggles that you, or someone you love, endure if you suffer from arthritis, degenerative joint disease, degenerative cartilage and ligaments, bone spurs, Bursitis and Tendinitis, or have been told you are bone-on-bone. We know that people who are diagnosed with these conditions are commonly treated with over-the-counter medications, prescription drugs, pain medicine, physical therapy, injections including cortisone, gel shots (Synvisc, Orthovisc, etc.), and surgery.

As these treatments are performed, the benefits and relief from many of these therapies are short-lived. The result for many of these conditions is major surgery, including total joint replacement, or a life with chronic pain and disability. Many have found success with Regenerative Medicine.

Regenerative therapy takes advantage of your bodys ability to repair itself naturally. The procedure is simple: healing cells are injected into your painful joint by one of our highly trained medical practitioners.

These regenerative cells stimulate an incredible healing force within your body. Over a few weeks to a few months, the cells and growth factors assist your bodys ability to potentially repair and regenerate cartilage, ligaments, muscles, tissues and nerves.

This simple in-office procedure can have an incredible impact on your function, and restore your pain-free life. Regenerative therapy is safe and effective at potentially repairing damaged tissue and reducing pain, while improving your mobility.

Regenerative Medicine of South Jersey holds educational seminars that include vital information on the healing potential of these cells. Visit us online at http://www.regenerativemedicineofsj.com, and call Regenerative Medicine of South Jersey at (609) 886-8039 to register for an informational seminar.

See original here:
Regenerative Medicine May be the Answer for Your Chronic Pain - Cape May County Herald

Posted in Regenerative Medicine | Comments Off on Regenerative Medicine May be the Answer for Your Chronic Pain – Cape May County Herald

At the American Academy of Stem Cell Physicians Live Congress 2019, FDA Safety Panel Says No to the Bad Actors – PRNewswire

Posted: November 8, 2019 at 12:45 am

MIAMI, Nov. 7, 2019 /PRNewswire/ -- The American Academy of Stem Cell Physicians (AASCP) was joined by the alliance leader Janet Marchibroda in hosting a safety standards panel on Nov. 2 at the AASCP Live Congress 2019. The panel which was moderated by Janet Marchibroda, the president of The Alliance for cell therapy now, and included attendance via Skypeby Dr. Peter Marks, director of the Center for Biologics and Evaluation and Research was well-received by physicians from around the world.

The panel discussed safety precautions and considered guidelines for the safety of patients, calling out the bad actors in the field. They noted that current safety guidelines are antiquated and need revision to meet the demands of new cutting-edge medicine such as stem cells, which is a growing field in medical biologics.

Dr. A.J. Farshchian, a spokesperson forthe AASCP, was honored with the 2019 Visionary Award for his pioneering work with the AASCP and the stem cell industry. He said, "There's been too much talk but no action. We need to change that to ensure the safety of the patients who receive care. AASCP will gladly point out the bad actors to the FDA, are we telling on each other? Yes. Are we breaking the Code? No, we are just preserving what's left of this industry."

Later he added, "Many physicians and scientists are starting to believe that some of the regulations regarding stem cells which have been written many years ago have not kept up with the rapidly advancing science. These regulations must be revisited because they are all pass."

At the AASCP Live Congress, board certifications were also provided. To receive the board certification, physicians must meet stringent qualifications, including attending weekly meetings and pass a written and oral exam. The AASCP congratulates those who were recognized, including Dr. Rene Blaha, Dr. Warren Bleiweiss, Dr. Paula Marchionda and Dr. Kalpana Patel, all of whom received diplomat status; and Dr. Max Citrin, who received associate diplomat status.

The American Academy and its board also granted the title of associate professor and all rights therein to Dr. Richard Hull and Dr. Leonid Macheret. Dr. Richard Hull, who also earned tenure with the AASCP, said of the conference, "It is a great pleasure teaching this group of physicians. I love to teach and these physicians are so eager to learn."

To learn more about the AASCP, their educational initiatives and certification, visit AASCP.net.

About AASCP

The American Academy of Stem Cell Physicians (AASCP) is an organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatment, and prevention of disease related to or occurring within the human body. The AASCP aims to serve as an educational resource for physicians, scientists, and the public. To learn more, visit AASCP.net

Related Images

dr-farshchian.jpg Dr. Farshchian

SOURCE The American Academy of Stem Cell Physicians

https://www.aascp.net

Visit link:
At the American Academy of Stem Cell Physicians Live Congress 2019, FDA Safety Panel Says No to the Bad Actors - PRNewswire

Posted in Regenerative Medicine | Comments Off on At the American Academy of Stem Cell Physicians Live Congress 2019, FDA Safety Panel Says No to the Bad Actors – PRNewswire

LaunchPad Medical Wins NIH HEAL Grant to Reduce Opioid Use and Addiction – PRNewswire

Posted: November 8, 2019 at 12:45 am

LOWELL, Mass., Nov. 5, 2019 /PRNewswire/ --LaunchPad Medical, Inc. announced that it has received a grant from the National Institutes of Health through its Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, to improve strategies for the prevention and treatment for opioid misuse and addiction. This Phase I Small Business Innovation Research (SBIR) grant (1R43DE029369-01) will fund the development of a dental bone graft formulation that will include the release of locally acting non-opioid pain medication. Once developed, this product is intended to be used to fill extraction sites and mitigate post-operative pain following the removal of wisdom teeth.

"Data shows that there is a statistically significant absolute risk increase in persistent opioid use and abuse following a single course of opiates prescribed after wisdom tooth extractions," said George Kay, DMD, MMSc, LaunchPad Medical's Chief Scientific Officer. Approximately 10 million wisdom teeth are removed annually in the United States.

"Preliminary studies have shown that medication can be incorporated into our biomaterial and released over time," said Rahul Jadia, PhD, who is the principal investigator for this grant, "and the release profile of a target drug can be tailored to elicit an ideal time-dose curve."

This grant complements the existing grants that LaunchPad Medical has received from the NIH-funded Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center (U24DE026915) which was formed to improve the translation of promising tissue engineering and regenerative medicine technologies for dental, oral, and craniofacial clinical practice. Funding from the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center has enabled LaunchPad Medical to develop and optimize a dental graft based on the company's Tetranite technology that resorbs and is replaced by bone on a timescale commensurate with existing graft materials but does not require ancillary fixation or containment devices like most other dental graft materials.

"The incorporation of therapeutics into this bone grafting material would further increase the value proposition and clinical utility of this product," said David Kohn, PhD, Director of the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center.

About LaunchPad Medical, Inc.

LaunchPad Medical, Inc. is a medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite. The company is initially developing this technology for use in the dental market, and recently initiated its first-in-man clinical study for implant stabilization. The company is also working to develop adhesive applications for the broader orthopedics market. LaunchPad Medical's Tetranite technology is not yet approved for commercial use.

SOURCE LaunchPad Medical, Inc.

https://www.nih.gov/news-events/news-releases/nih-funds-945-million-research-tackle-national-opioid-crisis-through-nih-heal-initiative

Visit link:
LaunchPad Medical Wins NIH HEAL Grant to Reduce Opioid Use and Addiction - PRNewswire

Posted in Regenerative Medicine | Comments Off on LaunchPad Medical Wins NIH HEAL Grant to Reduce Opioid Use and Addiction – PRNewswire

BioLife Solutions Named one of the Fastest Growing Companies in North America on Deloitte’s 2019 Technology Fast 500(TM) – NBC Right Now

Posted: November 8, 2019 at 12:45 am

BOTHELL, Wash., Nov. 7, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that based on revenue growth from 2015 to 2018, it has been selected for inclusion on the Deloitte 2019 Technology Fast 500 list.

Mike Rice, BioLife President and CEO, commented, "We appreciate this recognition of our revenue growth over the last few years. We are focused on building a much larger, world-class enterprise supplying novel and enabling bioproduction tools to the cell and gene therapy industry."

About Deloitte's 2019 Technology Fast 500

Now in its 25th year, Deloitte's Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies both public and private in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2015 to 2018.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least US $50,000, and current-year operating revenues of at least US $5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About BioLife Solutions

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools. Our proprietary CryoStor freeze media and HypoThermosol shipping and storage media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our recently acquired ThawSTAR family of automated cell thawing products and evo cold chain management system reduce therapeutic and economic risk for cell and gene therapy developers by reducing the potential of administering a non-viable dose. For more information, please visit http://www.biolifesolutions.com and follow BioLife on Twitter.

Cautions Regarding Forward Looking Statements

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the company's anticipated business and operations, potential revenue growth and market expansion, and projected financial results. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of our products; market volatility; competition; litigation;the ability of the company to implement its business strategy and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor RelationsRoderick de GreefChief Financial Officer(425) 402-1400rdegreef@biolifesolutions.com

Go here to read the rest:
BioLife Solutions Named one of the Fastest Growing Companies in North America on Deloitte's 2019 Technology Fast 500(TM) - NBC Right Now

Posted in Regenerative Medicine | Comments Off on BioLife Solutions Named one of the Fastest Growing Companies in North America on Deloitte’s 2019 Technology Fast 500(TM) – NBC Right Now

Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN4001, First Multigenic Investigational Therapeutic Candidate for…

Posted: November 8, 2019 at 12:45 am

"We are excited to have reached this important milestone in the clinical evaluation of INXN-4001 for treatment of end-stage heart failure," stated Amit Patel, MD, MS, Co-Founder and Medical Director of TripleGene. "Heart failure rarely results from a single genetic defect, and while single gene therapy approaches have been studied, these treatments may not fully address the causes of the disease. Our unique multigenic approach is designed to stimulate biological activity targeting multiple points in the disease progression pathway."

Triple-Gene's investigational therapy uses non-viral delivery of a constitutively expressed multigenic plasmid designed to express human S100A1, SDF-1, and VEGF165 gene products, which affect progenitor cell recruitment, angiogenesis, and calcium handling, respectively, and target the underlying molecular mechanisms of pathological myocardial remodeling. The plasmid therapy is delivered via RCSI which allows for cardiac-specific delivery to the ventricle.

"Heart failure is the leading cause of death worldwide and represents a significant and growing global health problem. Aside from heart transplant and LVAD, current treatment options for those patients with end-stage disease are limited," commented Timothy Henry, MD, FACC, MSCAI, Medical Director of the Carl and Edyth Lindner Center for Research and Education at The Christ Hospital and a member of the Triple-Gene Medical Advisory Board. "The INXN4001 investigational therapy represents a biologically-based method focused on repairing the multiple malfunctions of cardiomyocytes, and I look forward to seeing the results of this initial safety study and further exploring the promise of this innovative treatment approach."

Triple-Gene will present preliminary data from the Phase 1 study at theAmerican Heart Association Scientific Sessionsat the Pennsylvania Convention Center in Philadelphia. A poster titled "Safety of First in Human Triple-Gene Therapy Candidate for Heart Failure Patients" will be presented on Sunday, November 17thfrom 3:00 pm - 3:30 pm ETin Zone 4 of the Science and Technology Hall.

About the Phase 1 Trial of INXN-4001INXN-4001 is being evaluated in a Phase I open label study in adult patients with implanted Left Ventricular Assist Device (LVAD). The study is designed to investigate the safety and feasibility of supplemental cardiac expression of S100A1, SDF-1 and VEGF-165 from a single, multigenic plasmid delivered via Retrograde Coronary Sinus Infusion (RCSI) in stable patients implanted with a LVAD for mechanical support of end-stage heart failure. Twelve stable patients with an implanted LVAD were allocated into 2 cohorts (6 subjects each) to evaluate the safety and feasibility of infusing 80mg of INXN4001 in either a 40mL (Cohort 1) or 80mL (Cohort 2) volume. The primary endpoint of safety and feasibility is assessed at the 6-month endpoint. Daily activity data are also collected throughout the study using a wearable biosensor. Dosing on both Cohorts 1 and 2 has been completed, and patients continue follow-up per protocol.

About Triple-GeneTriple-Gene LLC is a clinical stage gene therapy company focused on advancing targeted, controllable, and multigenic gene therapies for the treatment of complex cardiovascular diseases. The Company's lead product is a non-viral investigational gene therapy candidate that drives expression of three candidate effector genes involved in heart failure. Triple-Gene is a majority owned subsidiary ofIntrexon Corporation(NASDAQ: XON) co-founded by Amit Patel, MD, MS, and Thomas D. Reed, PhD, Founder and Chief Science Officer of Intrexon. Learn more about Triple-Gene atwww.3GTx.com.

About Intrexon CorporationIntrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with Better DNAto create biologically-based products that improve the quality of life and the health of the planet through two operating units Intrexon Health and Intrexon Bioengineering. Intrexon Health is focused on addressing unmet medical needs through a diverse spectrum of therapeutic modalities, including gene and cell therapies, microbial bioproduction, and regenerative medicine. Intrexon Bioengineering seeks to address global challenges across food, agriculture, environmental, energy, and industrial fields by advancing biologically engineered solutions to improve sustainability and efficiency. Our integrated technology suite provides industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA, and we invite you to discover more atwww.dna.comor follow us on Twitter at@Intrexon, onFacebook, andLinkedIn.

TrademarksIntrexon, Powering the Bioindustrial Revolution with Better DNA,and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Original post:
Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN4001, First Multigenic Investigational Therapeutic Candidate for...

Posted in Regenerative Medicine | Comments Off on Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN4001, First Multigenic Investigational Therapeutic Candidate for…

Page 1,283«..1020..1,2821,2831,2841,285..1,2901,300..»